EphA3, a novel target for leukaemia stem cell therapy

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1099381

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Patients with acute myeloid leukaemia often respond to therapy, but many relapse due to “leukemic stem cells” (LSC), the few cells in the original leukaemia which survive therapy. We focus on a protein (EphA3) which sits on LSCs and helps them interact with their environment. Disrupting this interaction may make these cells vulnerable to therapy. We aim to determine the function of EphA3 on LSCs and optimise the therapeutic use of an antibody against EphA3 which is currently in clinical trial.

Funded Activity Details

Start Date: 01-01-2016

End Date: 01-01-2019

Funding Scheme: Project Grants

Funding Amount: $616,992.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Haematological Tumours

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Eph receptors | antibody cancer therapy | leukaemia | mouse models | stem cell biology

Related Links